Saphnelo

Active Ingredient(s): Anifrolumab-fnia
FDA Approved: * July 30, 2021
Pharm Company: * ASTRAZENECA AB
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Saphnelo Overview

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE).[1][2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. ‹The template below is included via a redirect (Template:Mcn) that has been nominated for discussion. See redirects for discussion to help reach a consensus on what to do.›...

Read more Saphnelo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Anifrolumab

Recent Saphnelo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Anifrolumab-fnia
  • Injection: 300mg/2ml(150mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Saphnelo: (1 result)

Sorted by National Drug Code
  • 0310-3040 Saphnelo 300 mg/2ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Anifrolumab-fnia or a similar ingredient: (1 result)